Lena M. Wulfken

MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications of Serum miR-1233 Levels

Lena M. Wulfken, Rudolf Moritz, Carsten‐Henning Ohlmann et al. · PLoS ONE · 2011 · 230 citations · Full text

Medicine, Cancer Biology, Oncology +17

Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma

Stefan Hauser, Lena M. Wulfken, Stefan Holdenrieder et al. · Cancer Epidemiology · 2012 · 101 citations

Medicine, Molecular Medicine, Oncology +16

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Jürgen C. Becker, Selma Ugurel, Ulrike Leiter et al. · The Lancet · 2023 · 70 citations

Medicine, Immunology, Oncology +16

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients

Georg Lodde, Andrea Forschner, Jessica C. Hassel et al. · Cancers · 2021 · 27 citations · Full text

Medicine, Immunology, Oncology +17

Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study

Georg Lodde, Jessica C. Hassel, Lena M. Wulfken et al. · European Journal of Cancer · 2023 · 21 citations

Medicine, Dermatology, Oncology +14